Researchers in Australia have reprogrammed the RNA-cutting enzyme PspCas13b to destroy the fusion transcripts that drive many ...
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today ...
The ISSCR iPSC 20th Anniversary Symposium convenes the global stem cell community in Kyoto, the birthplace of iPSCs, to mark ...
Tuesday, November 3rd at 11:00am EST / 5:00pm CET Genome Safety Webinar Series: Regulatory Expectations, Practical Workflows, ...
There is currently no cure for Friedreich’s ataxia. However, CRISPR Medicine News spoke with Dr Céline Rocca about the importance of precision models and how she used CRISPR to develop a blood stem ...
With CRISPR/Cas9 moving from a research tool into adaption as personalized medicine, safety concerns have to be addressed: an understanding of the effects on the targeted gene, but also potential ...
A UCL-led team has developed a clinical-scale CRISPR-Cas9-AAV6 workflow intended to correct... China’s CRISPR Gene-Editing Trials: Insights from... Sep. 15, 2026 China is one of the two leading ...
The Federation of American Societies for Experimental Biology (FASEB) conference on Genome Engineering kicks off one month from now in Rome, Italy. The Federation of American Societies for ...
Clinical data presented at the ASGCT meeting in Baltimore last week revealed that Excision Biotherapeutics' CRISPR-based therapy for HIV is safe but doesn 't cure HIV. Data presented at the 27th ASGCT ...
A portable CRISPR-Cas13 assay detected mpox virus with 100% sensitivity and specificity in clinical samples from Sierra Leone. The SHINE test identified as few as 10 copies/µL and delivered results in ...
CRISPR-Cas12b technology was used to edit allogeneic donor islet cells for transplantation into a man with long-standing type 1 diabetes. Transplantation of donor islet cells could eliminate the need ...
A new CRISPR-based strategy turns cancer cells' own mutant transcripts against them, opening a potential route to one of oncology's most stubborn unsolved problems: the targeting of mutant p53. Rather ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results